CLINICAL TRIALS PROFILE FOR TRUVADA
✉ Email this page to a colleague
505(b)(2) Clinical Trials for TRUVADA
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT00641641 ↗ | The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection | Completed | Merck Sharp & Dohme Corp. | N/A | 2008-03-01 | The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system. |
| New Combination | NCT00641641 ↗ | The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection | Completed | Kirby Institute | N/A | 2008-03-01 | The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for TRUVADA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00074581 ↗ | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Completed | HIV Prevention Trials Network | Phase 3 | 2005-02-01 | This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not. |
| NCT00074581 ↗ | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2005-02-01 | This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not. |
| NCT00090779 ↗ | Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV | Terminated | Adult AIDS Clinical Trials Group | Phase 2 | 2005-01-01 | Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected. |
| NCT00090779 ↗ | Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2005-01-01 | Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRUVADA
Condition Name
Clinical Trial Locations for TRUVADA
Trials by Country
Clinical Trial Progress for TRUVADA
Clinical Trial Phase
Clinical Trial Sponsors for TRUVADA
Sponsor Name
